Is rubicatin/rubitidine a domestic or imported drug?

Lurbinectedin is a drug used to treat metastatic small cell lung cancer (SCLC). Its trade name is ZEPZELCA. As a new type of anti-cancer drug, rubitidine was developed from the Spanish pharmaceutical company PharmaMar and is an imported drug. Although the drug has been approved and launched in the Chinese market, its production still mainly relies on overseas pharmaceutical factories and is therefore considered an imported drug.

Rubitidine is an alkylating agent that exerts anti-tumor effects by interfering with the DNA synthesis process of cancer cells. For the treatment of metastatic small cell lung cancer, the drug has shown relatively good efficacy in clinical trials, especially for patients who have failed to respond to traditional treatment options. Therefore, the launch of rubitidine in the Chinese market provides a new treatment option for patients with small cell lung cancer, especially those with drug resistance or recurrence.

Rubitin will be fully launched in China in 2025. Although it faces high pricing pressure as an imported drug, it provides patients with a new chance of survival, especially in the face of treatment failure. Currently, as the demand for anti-cancer drugs in the Chinese market increases, more and more imported drugs are introduced, which to a certain extent promotes the innovation of domestic treatment options.

However, although rubitidine is still an imported drug, with the development of domestic pharmaceutical technology, a domestic version may appear in the future. Domestic pharmaceutical companies are strengthening cooperation with international pharmaceutical companies to promote the production of generic drugs of original drugs in order to provide patients with more treatment options and more affordable prices.

Reference materials:https://www.zepzelca.com/